Gennova vax gets nod for ph 2/3 trials

[email protected]12 Oct, 2021News

India?s first mRNA-based Covid-19 vaccine candidate HGCO19 by Gennova Biopharmaceuticals Ltd has been granted approval for phase 2/3 clinical trails, the department of biotechnology (DBT) said on Tuesday. The Pune-based biotechnology company had submitted the interim clinical data of the vaccine?s phase 1 study to the central drugs standard control organisation, it said.